Physiologically based pharmacokinetic (PBPK) model to predict the magnitude of drug-drug interaction between vincristine and the azole antifungals isavuconazole, posaconazole, and voriconazole in children. (PubMed, Antimicrob Agents Chemother) - Jul 23, 2026 - "In CYP3A5 extensive metabolizers (EMs), vincristine AUCinf ratios ranged from 1.22- to 1.38-fold, 1.19- to 1.24-fold, and 1.05- to 1.07-fold for isavuconazole, posaconazole, and voriconazole, respectively. The model predicted vincristine AUCinf >100 ng·h/mL in CYP3A5 PM and <100 ng·h/mL in CYP3A5 EM; therefore, vincristine dose reduction may be required only in CYP3A5 null expressors."
Journal • PK/PD data • Hematological Malignancies • Infectious Disease • Leukemia • Oncology • Pediatrics • Pulmonary Disease • Respiratory Diseases • CYP3A4 • CYP3A5
|
|
Amit Desai; Laura Lynn Kovanda; Mary P Choules; Peter L Bonate; Roger J Brüggemann; Yukio Otsuka
|